Veriton Pharma Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Veriton Pharma Ltd. - overview
Established
1997
Location
Weybridge, Surrey, UK
Primary Industry
Pharmaceuticals
About
Veriton Pharma Ltd. is a pharmaceutical company focused on developing and manufacturing high-quality medicinal products, particularly for epilepsy, neurology, and rare pediatric conditions. Their expertise is anchored in over two decades of experience in healthcare. Founded in 1997 and headquartered in Weybridge, UK, Veriton Pharma Ltd.
specializes in the pharmaceutical sector, producing prescription medicines that address unmet medical needs. The company was acquired by SERB S. a. r.
l. , a portfolio company of Charterhouse Capital Partners, in May 2020. No information on any previous founders is available. Veriton Pharma specializes in the development and manufacture of high-quality medicinal products aimed at addressing unmet medical needs, particularly in the fields of epilepsy, neurology, and rare pediatric conditions.
The company's core offerings encompass a portfolio of prescription medicines, leveraging over 20 years of experience from a renowned children’s hospital in London. These specialized products improve patient quality of life and are distributed globally, serving hospitals and prescribers in Europe, the United States, and other regions with significant healthcare infrastructure. Their commitment to quality is evident in adherence to regulated manufacturing standards. In 2023, Veriton Pharma generated a revenue of USD 26.
77 mn and an EBITDA of USD 9. 40 mn, driven through direct transactions with healthcare providers, including hospitals and prescribers. The company operates on a business-to-business model, with a focus on tailored pricing for customers, especially the NHS. The flagship products in the epilepsy and neurology sectors significantly contribute to revenue streams, reflecting the need for specialized therapeutic solutions.
Veriton Pharma plans to expand its product line with new offerings targeting the neurology and pediatric markets, with anticipated launches in the next few years. The company is also focusing on entering new geographical markets, particularly in North America and Asia, by 2025. The funding from the acquisition by SERB S. a.
r. l. will support these initiatives, enhancing their capacity for research and development and facilitating market entry.
Current Investors
SERB S.a.r.l.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.veritonpharma.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Veriton Pharma Ltd. - timeline of key events
Veriton Pharma Ltd. - financials
| Fiscal Year Ended | Jan 31, 2012 | Jan 31, 2013 | Jan 31, 2014 | Jan 31, 2015 | Jan 31, 2016 | Jan 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 8,019,989 | 8,353,458 | 8,290,742 | 9,186,380 | - | - | 11,467,115 | 16,692,941 | 16,281,211 | 16,173,929 | 16,232,041 | - | - | - |
| % Revenue Growth (YoY) | - | 4.2% | (0.8%) | 10.8% | - | - | - | - | (2.5%) | (0.7%) | 0.4% | - | - | - |
| EBITDA (USD) | 1,008,120 | 824,147 | (287,081) | 638,176 | - | - | (38,675) | 1,001,133 | 1,470,432 | 4,383,252 | 4,226,678 | - | - | - |
| Operating Income (USD) | 905,413 | 738,285 | (358,746) | 587,833 | - | - | (112,910) | 895,250 | 1,384,261 | 4,320,158 | 4,180,952 | - | - | - |
| Operating Margin | 11.3% | 8.8% | (4.3%) | 6.4% | - | - | (1.0%) | 5.4% | 8.5% | 26.7% | 25.8% | - | - | - |
| % EBITDA Margin | 12.6% | 9.9% | (3.5%) | 6.9% | - | - | (0.3%) | 6.0% | 9.0% | 27.1% | 26.0% | - | - | - |
| NET Income (USD) | 789,974 | 915,829 | (78,103) | 590,292 | - | - | 80,432 | 844,379 | 1,640,145 | 4,086,749 | 3,460,631 | - | - | - |
| % Net Margin | 9.9% | 11.0% | (0.9%) | 6.4% | - | - | 0.7% | 5.1% | 10.1% | 25.3% | 21.3% | - | - | - |
Veriton Pharma Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Veriton Pharma Ltd. | - |
Displaying 1 - 1 of 1
Veriton Pharma Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.